Wahlstrom Mats — SEC Form 4 filings
SEC reporting owner CIK 1459154. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-09.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-05 to 2026-06-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 75,727 shares, $221,607 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 99,988 shares, $73,881 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 60,000 shares @ $2.53 ($151,800) in TriSalus Life Sciences, Inc., filed 2026-05-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | Director | 8 | 4 legs · 75,727 sh · $221,607 | — | 7 |
| Coherus Oncology, Inc. (CHRS) | Director | 6 | — | 1 leg · 99,988 sh · $73,881 | 10 |
Form 4 filings — Wahlstrom Mats
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-09 | 4 | Coherus Oncology, Inc. (CHRS) | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 60,000 @ $2.53 | EDGAR |
| 2026-05-15 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 37,602 @ $0 · Grant/award (A): 34,226 @ $0 · Grant/award (A): 75,204 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Coherus Oncology, Inc. (CHRS) | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | Coherus BioSciences, Inc. (CHRS) | Sale (S): 99,988 @ $0.74 | EDGAR |
| 2025-02-11 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Other (J): 44,750 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 25,188 @ $3.97 | EDGAR |
| 2024-11-25 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 5,000 @ $4.55 | EDGAR |
| 2024-11-22 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 2,040 @ $4.16 · Purchase (P): 8,687 @ $4.44 | EDGAR |
| 2024-08-21 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Coherus BioSciences, Inc. (CHRS) | Grant/award (A): 112,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Coherus BioSciences, Inc. (CHRS) | Gift (G): 99,988 @ $0 · Gift (G): 99,988 @ $0 | EDGAR |
| 2024-02-05 | 4 | Coherus BioSciences, Inc. (CHRS) | Option exercise (M): 14,997 @ $1.67 · Option exercise (M): 44,991 @ $1.67 · Option exercise (M): 14,997 (derivative) @ $0 · Option exercise (M): 44,991 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1459154 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →